The mission of the Arizona Cancer Center (AZCC) is to prevent and cure cancer. To continue that mission, this application requests a 5-year renewal of the Cancer Center Support Grant (CCSG). The AZCC was founded as a Division of the College of Medicine (COM), University of Arizona (UA) in 1976. It obtained a CCSG in 1978 and was designated a Comprehensive Cancer Center by the NCI in 1990. To accomplish our mission, the basic and translational/clinical and cancer prevention and control research is carried out in six programs, including molecular genetics, cancer metastases and signaling, cancer imaging and technology, gastrointestinal cancer, therapeutic development and cancer prevention and control. These programs are supported by 20 shared services, which help the AZCC (the whole) be greater than the sum of the parts. Since the last renewal, the AZCC team has substantially increased their peer reviewed funding and garnered additional program projects and a GI cancer SPORE. Those accomplishments demonstrate the interdisciplinary activities of the Cancer Center. As we hope the reviewers will see, the team has made considerable progress in their basic and clinical science, including bringing two therapeutic and five prevention agents forward into clinical trials. The renewal outlined in this application is critical to keep us working to accomplish our mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-30
Application #
7261982
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1978-09-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2009-06-30
Support Year
30
Fiscal Year
2007
Total Cost
$4,124,404
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Knudsen, Erik S; Balaji, Uthra; Mannakee, Brian et al. (2018) Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut 67:508-520
Boese, Cody J; Nye, Jonathan; Buster, Daniel W et al. (2018) Asterless is a Polo-like kinase 4 substrate that both activates and inhibits kinase activity depending on its phosphorylation state. Mol Biol Cell 29:2874-2886
Sohail, Atif; Mushtaq, Adeela; Iftikhar, Ahmad et al. (2018) Emerging immune targets for the treatment of multiple myeloma. Immunotherapy 10:265-282
Doane, Cynthia J; Patil, Karuna; Hoffman, Emely A et al. (2018) Supernumerary Incisors in CB6F1 Mice Conditioned with Chemotherapy and Total Body Irradiation before Bone Marrow Transplantation. Comp Med 68:349-352
Bea, J W; Hsu, C-H; Blew, R M et al. (2018) Use of iDXA spine scans to evaluate total and visceral abdominal fat. Am J Hum Biol 30:
Lent, Adrienne B; O'Connor, Patrick A; Reikowsky, Ryan C et al. (2018) Quit outcomes among clients ineligible for cessation medication through the state quitline: a retrospective, observational study. BMC Public Health 18:1001
Bulkley, Joanna E; McMullen, Carmit K; Grant, Marcia et al. (2018) Ongoing ostomy self-care challenges of long-term rectal cancer survivors. Support Care Cancer 26:3933-3939
Zaim, Samir Rachid; Li, Qike; Schissler, A Grant et al. (2018) Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses. Pac Symp Biocomput 23:484-495
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233

Showing the most recent 10 out of 1336 publications